Loading stock data…
Valneva SE (VALN)
$6.85-0.04 (-0.58%)
Market ClosedLast close Sep 8
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Valneva SE in the Healthcare sector is trading at $6.85 with a market capitalization of $507M. Wall Street consensus targets $12.25 (4 analysts), implying a +78.8% move over the next 12 months. The stock is currently 44% below its 52-week high of $12.23, remaining 7.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +78.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $30.90M↓ | $47.69M↑ | $29.41M↓ | $48.33M↓ | $49.23M |
| Gross Profit | $4.72M↓ | $11.62M↑ | $5.50M↓ | $24.21M↓ | $26.19M |
| Operating Income | -$23.70M↑ | -$27.68M↑ | -$37.35M↓ | -$10.64M↓ | -$5.96M |
| Net Income | -$32.07M↑ | -$50.02M↓ | -$44.35M↓ | -$11.59M↓ | -$9.23M |
Peer Comparison
JNJUNHPFE
Fundamentals
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$507.31M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-179.97%
Volume
Today's trading volume
28,331
Recent News
The Bull Case For Pfizer (PFE) Could Change Following New COVID And Lyme Vaccine Milestones - Learn Why
In August 2026, Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG variant for high-risk individuals, while Pfizer and Valneva’s Lyme disease vaccine candidate PF-07307405 had its Marketing Authorization Application validated by the European Medicines Agency based on Phase 3 trial data. Together, these vaccine milestones highlight Pfizer’s ongoing role in infectious disease prevention across both seasonal COVID-19 protection and...
Pfizer (PFE) Starts EMA Review For Its Lyme Disease Vaccine
Pfizer (NYSE:PFE) and Valneva announced that the European Medicines Agency has validated the Marketing Authorization Application for their Lyme disease vaccine candidate, PF-07307405. The validation starts the EMA regulatory assessment process for what could become a first in class Lyme disease vaccine for use in both North America and Europe. The application is supported by Phase 3 efficacy data, with the companies highlighting an unmet medical need in Lyme disease prevention. This move by...
Valneva (VALN) Q2 2026 Earnings Call Transcript
Restructuring efforts and Lyme vaccine regulatory timeline take center stage.
Pfizer (PFE) Gets EMA Lyme Vaccine Filing Validation As ADC Patent Clout Grows
Pfizer (NYSE:PFE) and Valneva had their Marketing Authorization Application for a Lyme disease vaccine candidate validated by the European Medicines Agency, confirming it is ready for full review. The vaccine filing follows late stage clinical results that reported encouraging efficacy and safety in preventing Lyme disease. A recent patent report highlighted Pfizer as a leading holder of next generation antibody drug conjugate intellectual property in cancer treatment. For readers looking...
Pfizer (PFE) Stock Looks Reasonable On Returns But Stretched On Earnings
Pfizer stock has delivered a roughly 28% decline over the past five years, yet recent gains and a mixed set of valuation checks mean the current price is not an obvious bargain or clear bubble. With fresh product news and shifting expectations around its portfolio, investors are weighing whether the recent rebound leaves enough room for attractive long term returns. The share price is down about 28% over five years. This points to a company that has yet to fully reward long term holders...